In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles
- PMID: 19007246
- DOI: 10.1021/ac801882g
In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles
Abstract
The biodistribution and urinary excretion of different surface-modified silica nanoparticles (SiNPs) in mice were investigated in situ using an in vivo optical imaging system. Three types of surface-modified SiNPs, including OH-SiNPs, COOH-SiNPs, and PEG-SiNPs with a size of approximately 45 nm, have been prepared with RuBPY doped for imaging purposes. Intravenous (i.v.) injection of these SiNPs followed by fluorescence tracing in vivo using the Maestro in vivo imaging system indicated that OH-SiNPs, COOH-SiNPs, and PEG-SiNPs were all cleared from the systemic blood circulation, but that both the clearance time and subsequent biological organ deposition were dependent on the surface chemical modification of the SiNPs. Thus, for instance, the PEG-SiNPs exhibited relatively longer blood circulation times and lower uptake by the reticuloendothelial system organs than OH-SiNPs and COOH-SiNPs. More interestingly, in vivo real-time imaged dominant signal in bladder and urine excretion studies revealed that all three types of i.v.-injected SiNPs with a size of approximately 45 nm were partly excreted through the renal excretion route. These conclusions were further confirmed through ex vivo organ optical imaging and TEM imaging and energy-dispersed X-ray spectrum analysis of urine samples. These findings would have direct implications for the use of SiNPs as delivery systems and imaging tools in live animals. Furthermore, our results demonstrate that the in vivo optical imaging method is helpful for in vivo sensing the biological effects of SiNPs by using luminescent dye doped in the silica matrix as a synchronous signal.
Similar articles
-
One-pot synthesis of sustained-released doxorubicin silica nanoparticles for aptamer targeted delivery to tumor cells.Nanoscale. 2011 Jul;3(7):2936-42. doi: 10.1039/c0nr00913j. Epub 2011 May 27. Nanoscale. 2011. PMID: 21623439
-
Chemical-modification-enhanced dielectrophoretic assembly of controllable and reversible silica submicrowires from nanoparticles.Langmuir. 2010 Oct 5;26(19):15155-60. doi: 10.1021/la1019636. Langmuir. 2010. PMID: 20726610
-
In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer.Colloids Surf B Biointerfaces. 2009 Sep 1;72(2):303-11. doi: 10.1016/j.colsurfb.2009.04.017. Epub 2009 May 3. Colloids Surf B Biointerfaces. 2009. PMID: 19450955
-
Functionalized silica nanoparticles: a platform for fluorescence imaging at the cell and small animal levels.Acc Chem Res. 2013 Jul 16;46(7):1367-76. doi: 10.1021/ar3001525. Epub 2013 Mar 14. Acc Chem Res. 2013. PMID: 23489227 Review.
-
Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage.Nanomedicine (Lond). 2012 Jan;7(1):111-20. doi: 10.2217/nnm.11.166. Nanomedicine (Lond). 2012. PMID: 22191780 Review.
Cited by
-
Secondary nuclear targeting of mesoporous silica nano-particles for cancer-specific drug delivery based on charge inversion.Oncotarget. 2016 Oct 25;7(43):70100-70112. doi: 10.18632/oncotarget.12149. Oncotarget. 2016. PMID: 27661121 Free PMC article.
-
Industrialization's eye view on theranostic nanomedicine.Front Chem. 2022 Aug 19;10:918715. doi: 10.3389/fchem.2022.918715. eCollection 2022. Front Chem. 2022. PMID: 36059870 Free PMC article. Review.
-
Promising plasmid DNA vector based on APTES-modified silica nanoparticles.Int J Nanomedicine. 2012;7:1061-7. doi: 10.2147/IJN.S28267. Epub 2012 Feb 23. Int J Nanomedicine. 2012. PMID: 22403488 Free PMC article.
-
Color Doppler ultrasound and gamma imaging of intratumorally injected 500 nm iron-silica nanoshells.ACS Nano. 2013 Jul 23;7(7):6367-77. doi: 10.1021/nn402507d. Epub 2013 Jul 1. ACS Nano. 2013. PMID: 23802554 Free PMC article.
-
Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment.Biomater Res. 2021 Jun 16;25(1):20. doi: 10.1186/s40824-021-00221-x. Biomater Res. 2021. PMID: 34134773 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical